Previous 10 | Next 10 |
2024-05-08 07:06:13 ET More on AstraZeneca AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca PLC (AZN) Q1 2024 Earnings Call Transcript AstraZeneca invests $140M in Cellectis, raising stake to 44% ...
2024-05-07 08:00:17 ET Eliana Merle from UBS issued a price target of $151.00 for MRNA on 2024-05-07 07:03:00. The adjusted price target was set to $151.00. At the time of the announcement, MRNA was trading at $122.13. The overall price target consensus is at $164.75 wit...
2024-05-04 16:47:00 ET The healthcare sector had 24 companies reporting their quarterly earnings this week, with 16 of them beating their topline numbers for the quarter.... Read the full article on Seeking Alpha For further details see: 16 out of 24 health care companies be...
2024-05-03 09:31:56 ET Summary BioNTech is a biotech company with a strong cash position and a commercial program generating cash flow, making it a promising investment opportunity. The company's pipeline includes programs targeting cancer, respiratory infections, and other diseas...
2024-05-02 18:36:00 ET Moderna (NASDAQ: MRNA) was a fine stock to heal an ailing portfolio on the second-to-last trading day of the week. The company, which developed and sells the Spikevax COVID-19 vaccine, saw its share price balloon by almost 13% thanks to an encouraging set of q...
2024-05-02 15:32:05 ET Summary CytomX Therapeutics, Inc. results from phase 1a dose-escalation study, using CX-904 for the treatment of patients with EGFR expressing solid tumors, expected with Q1 2024 earnings on May 8, 2024. Pending positive data, plus at the discretion of partn...
2024-05-02 13:48:51 ET More on Moderna Moderna, Inc. (MRNA) Q1 2024 Earnings Call Transcript Moderna, Inc. 2024 Q1 - Results - Earnings Call Presentation Moderna Investors Should Beware Patent-Dispute Fallout Moderna tops forecasts in Q1 despite COVID-related...
2024-05-02 13:46:08 ET More on Metagenomi, Inc. Stocks To Watch: Eyes On Broadcom, Target, Costco, Rivian And Small Caps Metagenomi, Moderna terminate gene editing collaboration Jefferies, BMO bullish on newly public Metagenomi Historical earnings data for Me...
2024-05-02 12:30:13 ET Image source: The Motley Fool. Moderna (NASDAQ: MRNA) Q1 2024 Earnings Call May 02, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Moderna (MRNA) Q1 2024 Earnings Call Transcript
2024-05-02 11:20:10 ET Moderna, Inc. (MRNA) Q1 2024 Earnings Conference Call May 02, 2024 08:00 A.M. ET Company Participants Lavina Talukdar - SVP & Head of IR Stéphane Bancel - CEO Stephen Hoge - President Jamey Mock - CFO Conference Call Part...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...